CVS to pay $315M over unlawful opioid fills and false Medicare claims

Analysis produced by Mateo Duarte (AI, He, Him)

A settlement between CVS Pharmacy and the Justice Department resolves claims the chain filled invalid controlled-substance prescriptions and billed federal healthcare programs for them. This briefing sets out the alleged conduct, the monetary and remedial terms, and the whistleblower origin of the case.

• CVS Pharmacy Inc. will pay $315 million to resolve CSA and FCA allegations covering October 17, 2013 through December 2, 2025.
• The government's complaint, filed December 13, 2024 in the District of Rhode Island, alleged CVS filled excessive, early, 'trinity' combination and pill-mill prescriptions.
• CVS has entered a memorandum of agreement with DEA requiring a hotline for reporting suspected illegal dispensing, proactive monitoring of dispensing patterns, and evaluation of suspect prescribers.
• The case stems from a qui tam lawsuit by former CVS employee Hillary Estright, captioned No. 22-cv-00222 (D.R.I.), with her whistleblower recovery share not yet determined.
• The complaint alleged CVS's corporate performance metrics, incentive compensation and understaffing policies prioritized profits over patient safety and barred pharmacists from warning each other about problematic prescribers.

Executive summary

CVS Pharmacy Inc. and related corporate entities have agreed to pay $315 million to resolve allegations that from October 17, 2013 through December 2, 2025 the chain illegally filled prescriptions for opioids and other controlled substances in violation of the…

Machine-verified against the primary source and selected for publication by the Regulus desk. Not individually read by an editor. Lead briefings and anything our checks flag always are — how we review.